Dose Finding Safety Study of VAL201 in Cancer Patients

NCT02280317 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage III Prostate Carcinoma
Stage IV Prostate Carcinoma

Interventions

DRUG: VAL201

Sponsor

ValiRx Plc